Makale detayı · 2021
Chronic kidney disease and neurological disorders: are uraemic toxins the missing piece of the puzzle?
- Yıl
- 2021
- Tür
- article
Veri kaynağı ayrımı
- YÖKSİS YÖKSİS makale kaydı
- YÖKSİS dergi adı Nephrology Dialysis Transplantation
- Katalog eşleşmesi (ISSN) Nephrology Dialysis Transplantation
- OpenAlex OpenAlex zenginleştirmesi (özet, atıf, konular)
Özet
OpenAlex · İngilizce
Chronic kidney disease (CKD) perturbs the crosstalk with others organs, with the interaction between the kidneys and the heart having been studied most intensively. However, a growing body of data indicates that there is an association between kidney dysfunction and disorders of the central nervous system. In epidemiological studies, CKD is associated with a high prevalence of neurological complications, such as cerebrovascular disorders, movement disorders, cognitive impairment and depression. Along with traditional cardiovascular risk factors (such as diabetes, inflammation, hypertension and dyslipidaemia), non-traditional risk factors related to kidney damage (such as uraemic toxins) may predispose patients with CKD to neurological disorders. There is increasing evidence to show that uraemic toxins, for example indoxyl sulphate, have a neurotoxic effect. A better understanding of factors responsible for the elevated prevalence of neurological disorders among patients with CKD might facilitate the development of novel treatments. Here, we review (i) the potential clinical impact of CKD on cerebrovascular and neurological complications, (ii) the mechanisms underlying the uraemic toxins' putative action (based on pre-clinical and clinical research) and (iii) the potential impact of these findings on patient care.
Konular
Atıflar
OpenAlex cited_by_count. WoS veya Scopus atıf sayısı değildir; o kaynaklar için ayrı kolon yoktur.
101 atıf
OpenAlex cited_by_count (önbellek / veritabanı)
Yerel katalogda bu makaleye atıf yapan 14 yayın (OpenAlex referans eşleşmesi; tam dünya listesi değildir).
- Acidosis, cognitive dysfunction and motor impairments in patients with kidney disease 2021
- Cognitive impairment in CKD patients: a guidance document by the CONNECT network. 2025
- Drugs with a negative impact on cognitive function (Part 1): chronic kidney disease as a risk factor 2023
- The role of the intestinal microbiome in cognitive decline in patients with kidney disease 2025
- Methodological challenges and biases in the field of cognitive function among patients with chronic kidney disease 2023
- Genetic and circulating biomarkers of cognitive dysfunction and dementia in CKD. 2025
- Drugs with a negative impact on cognitive functions (part 3): antibacterial agents in patients with chronic kidney disease. 2024
- Brain dysfunction in tubular and tubulointerstitial kidney diseases 2021
- Animal models to study cognitive impairment of chronic kidney disease 2024
- Translational research on cognitive impairment in chronic kidney disease 2024